Aegis began coverage on shares of Cogentix Medical (NASDAQ:CGNT) in a research note issued to investors on Friday morning. The firm issued a buy rating and a $4.75 price objective on the medical device company’s stock.

A number of other analysts have also recently commented on the company. JMP Securities started coverage on Cogentix Medical in a research report on Friday, October 6th. They set an outperform rating and a $5.00 target price on the stock. Roth Capital started coverage on Cogentix Medical in a research report on Wednesday, November 8th. They set a buy rating and a $4.00 target price on the stock. TheStreet upgraded Cogentix Medical from a d+ rating to a c rating in a research report on Thursday, November 9th. Finally, Zacks Investment Research upgraded Cogentix Medical from a hold rating to a buy rating and set a $2.50 target price on the stock in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Buy and an average price target of $4.06.

Cogentix Medical (NASDAQ:CGNT) traded up $0.19 on Friday, hitting $3.05. The stock had a trading volume of 180,700 shares, compared to its average volume of 62,524. Cogentix Medical has a twelve month low of $1.55 and a twelve month high of $3.26.

Hedge funds have recently modified their holdings of the stock. Broadfin Capital LLC increased its position in Cogentix Medical by 45.2% in the 2nd quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock valued at $1,905,000 after acquiring an additional 340,771 shares during the period. Renaissance Technologies LLC increased its position in Cogentix Medical by 2.3% in the 1st quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock valued at $1,013,000 after acquiring an additional 12,459 shares during the period. Dimensional Fund Advisors LP acquired a new position in Cogentix Medical in the 3rd quarter valued at about $152,000. Finally, Northern Trust Corp increased its position in Cogentix Medical by 0.4% in the 2nd quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after acquiring an additional 326 shares during the period. Hedge funds and other institutional investors own 13.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cogentix Medical (CGNT) Research Coverage Started at Aegis” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/cogentix-medical-cgnt-research-coverage-started-at-aegis/1743313.html.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.